Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M5JI
|
|||
| Former ID |
DNC000897
|
|||
| Drug Name |
Luvox
|
|||
| Synonyms |
FLUVOXAMINE MALEATE; 61718-82-9; Fevarin; Luvox CR; Fluvoxamine (maleate); UNII-5LGN83G74V; DU23000; DU-23000; SME 3110; 5LGN83G74V; MK-264; 54739-18-3; 5-Methoxy-4'-trifluoromethylvalerophenone (E)-O-2-aminoethyloxime monomaleate; 5-Methoxy-4'-(trifluoromethyl)valerophenone (E)-O-(2-aminoethyl)oxime, maleate (1:1); 54739-20-7; 1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime, (E)-, (Z)-2-butenedioate (1:1); C19H25F3N2O6
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Anxiety disorder [ICD-11: 6B00-6B0Z; ICD-10: R45.0] | Approved | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H25F3N2O6
|
|||
| Canonical SMILES |
COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F.C(=CC(=O)O)C(=O)O
|
|||
| InChI |
1S/C15H21F3N2O2.C4H4O4/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18;5-3(6)1-2-4(7)8/h5-8H,2-4,9-11,19H2,1H3;1-2H,(H,5,6)(H,7,8)/b20-14+;2-1-
|
|||
| InChIKey |
LFMYNZPAVPMEGP-PIDGMYBPSA-N
|
|||
| CAS Number |
CAS 61718-82-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
454745, 855640, 7847889, 11528686, 12013347, 14905575, 17405058, 23991201, 24278162, 26719775, 44701492, 46386804, 49681623, 49833812, 50106274, 50106275, 53777601, 53787474, 56311599, 56322576, 56424073, 57372756, 78691046, 91011981, 92125995, 92303795, 92712462, 99437098, 103486223, 103914603, 104179110, 121361195, 121363666, 124757174, 125163978, 126625489, 126656699, 131321166, 134340192, 135004590, 135060340, 135692110, 135698078, 137267463, 144076080, 152100561, 160871270, 162173304, 162263446, 163392548
|
|||
| ChEBI ID |
CHEBI:5139
|
|||
| ADReCS Drug ID | BADD_D00951 | |||
| SuperDrug ATC ID |
N06AB08
|
|||
| SuperDrug CAS ID |
cas=054739183
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium ruminantium
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Fluvoxamine maleate can be metabolized by Bifidobacterium ruminantium (log2FC = -0.348; p = 0.04). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia hansenii DSM20583
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Fluvoxamine maleate can be metabolized by Blautia hansenii DSM20583 (log2FC = -0.537; p = 0.019). | |||
|
Studied Microbe: Clostridium sp.
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Fluvoxamine maleate can be metabolized by Clostridium sp. (log2FC = -0.541; p = 0.016). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Serotonin transporter (SERT) | Target Info | Modulator | [3] |
| KEGG Pathway | Serotonergic synapse | |||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | 5HT1 type receptor mediated signaling pathway | |||
| 5HT2 type receptor mediated signaling pathway | ||||
| 5HT3 type receptor mediated signaling pathway | ||||
| 5HT4 type receptor mediated signaling pathway | ||||
| WikiPathways | Monoamine Transport | |||
| SIDS Susceptibility Pathways | ||||
| NRF2 pathway | ||||
| Synaptic Vesicle Pathway | ||||
| Serotonin Transporter Activity | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00743834) Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD). U.S. National Institutes of Health. | |||
| REF 2 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 3 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.